Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations. This strategic move brings Hand's extensive experience in legal, human resources, and corporate services to Tonix at a critical juncture. Hand's notable career includes significant contributions to Celgene's $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla® to Amgen. His expertise is expected to be invaluable as Tonix advances towards the potential launch of TNX-102 SL, its product candidate for fibromyalgia, pending FDA approval.
The appointment underscores Tonix's commitment to strengthening its leadership team in preparation for upcoming milestones. TNX-102 SL has completed two statistically significant phase 3 studies for fibromyalgia management and has received Fast Track designation from the FDA. The drug's development reflects Tonix's focus on addressing unmet needs in pain management and public health challenges. Additionally, the company's recent $34 million contract with the U.S. Department of Defense to develop TNX-4200 highlights its role in advancing medical solutions for biological threats.
Tonix's portfolio extends beyond fibromyalgia, with ongoing developments in central nervous system disorders, immunology, rare diseases, and infectious diseases. The company's state-of-the-art facilities and GMP-capable manufacturing underscore its capacity to respond to public health emergencies. For more details on Tonix Pharmaceuticals and its initiatives, visit https://www.TonixPharma.com. Investors seeking the latest updates on TNXP can find information in the company's newsroom at https://ibn.fm/TNXP.
